Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348228 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAGAATP53MAPT | |
| SCHEMBL29348324 | 0.76 | CYP3A4 (0.32) | — | |
| SCHEMBL17244886 | 0.73 | — | — | |
| SCHEMBL25629019 | 0.71 | GAA (0.41) | SMN1; SMN2LMNAGAATP53MAPT | |
| SCHEMBL17244887 | 0.70 | HRH1 (0.36) | SMN1; SMN2LMNAMAPTDPP8DPP9 | |
| SCHEMBL25509137 | 0.70 | KCNQ2 (0.31) | SMN1; SMN2DPP8DPP9 | |
| SCHEMBL24342186 | 0.69 | GAA (0.47) | SMN1; SMN2LMNAGAATP53MAPT | |
| SCHEMBL15823778 | 0.68 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAGAATP53MAPT | |
| SCHEMBL178982 | 0.68 | GAA (0.45) | SMN1; SMN2LMNAGAATP53MAPT | |
| SCHEMBL25509142 | 0.67 | HDAC6 (0.36) | SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |